{"product_id":"eurofins-bcg-matrix","title":"Eurofins Scientific Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEurofins Scientific’s BCG Matrix snapshot highlights a dynamic portfolio balancing high-growth diagnostics \"Stars\" with stable \"Cash Cows\" from legacy testing services, while a few niche offerings sit as \"Question Marks\" ripe for investment or divestment decisions. This concise preview teases quadrant placements and strategic implications, but the full BCG Matrix delivers quadrant-by-quadrant data, actionable recommendations, and editable Word\/Excel files to guide capital allocation and product strategy—purchase now for a ready-to-use roadmap to optimize Eurofins’ portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Discovery and Early Development Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Eurofins’ Biopharmaceutical Discovery and Early Development Services sits in the Stars quadrant after growing revenue ~18% CAGR 2022–2025 to roughly €1.1bn, outpacing the ~12% market CAGR for outsourced discovery.\u003c\/p\u003e\n\u003cp\u003eEurofins captured an estimated 14% market share in high-growth outsourced drug discovery as biotechs shifted spend externally for complex assays and ADME\/tox services.\u003c\/p\u003e\n\u003cp\u003eHeavy R\u0026amp;D and capex—≈€220m invested 2023–2025—target cell and gene therapy platforms, keeping this segment a primary growth engine and supporting \u0026gt;25% EBITDA margin expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Genomic and Specialized Clinical Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvanced Genomic and Specialized Clinical Diagnostics is a high-growth segment where Eurofins Scientific held ~28% global market share in prenatal and oncology testing in 2024 and reported segment revenue of €1.1bn in FY2024, up 22% YoY.\u003c\/p\u003e\n\u003cp\u003ePersonalized medicine and NGS (next-generation sequencing) drive demand; Eurofins launched 12 proprietary assays by 2024, often first-to-market, supporting a 35% CAGR in sample volume since 2021.\u003c\/p\u003e\n\u003cp\u003eHigh R\u0026amp;D spend sustains leadership: Eurofins invested €240m in R\u0026amp;D in 2024 (~6.2% of revenue), needed to fend off clinical lab entrants and protect assay IP.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgroscience Contract Research Organization Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins Scientific leads global agroscience contract research, delivering environmental safety and efficacy data for crop protection; its BioTesting segment reported €2.1bn revenue in 2024, with agroscience as a core growth driver.\u003c\/p\u003e\n\u003cp\u003eRising regulatory complexity and a shift to biological pesticides have increased demand—global regulatory testing spend for agrochemicals grew ~8% CAGR 2019–2024, pushing Eurofins to expand services.\u003c\/p\u003e\n\u003cp\u003eThe company invested €180m in global lab capacity in 2023–2024 to handle higher testing volumes from major agrochemical clients, supporting faster submission timelines and recurring contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Testing and Cybersecurity Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEurofins Scientifics Digital Testing and Cybersecurity Solutions sits as a Star: IoT device tests driven by a projected global IoT security market CAGR of ~26% (2024–30) and Eurofins reporting ~€120m in digital lab revenues in 2024, showing strong market share in certification for security and interoperability.\u003c\/p\u003e\n\u003cp\u003eThe unit needs steady capex—R\u0026amp;D and lab expansion—given rising zero‑day counts and evolving standards (e.g., ETSI, OWASP), but can scale rapidly via SaaS test platforms and global lab network.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 digital revenues ~€120m\u003c\/li\u003e\n\u003cli\u003eIoT security market CAGR ~26% (2024–30)\u003c\/li\u003e\n\u003cli\u003eHigh capex for R\u0026amp;D, labs, tools\u003c\/li\u003e\n\u003cli\u003eScalable via SaaS and global labs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Material Sciences and Semiconductor Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEurofins EAG labs are a Star: revenue from advanced material and semiconductor testing rose ~28% in 2024, driven by a $150B+ global onshoring push and \u0026gt;20% CAGR in semiconductor equipment spending (2023–25) that expanded Eurofins’ market share in failure analysis and surface characterization.\u003c\/p\u003e\n\u003cp\u003eThese services serve electronics and aerospace with high-margin testing (EBITDA margins ~25% in 2024) and face high barriers—capital optics, cleanroom investments, and PhD-level expertise—making it a premier, strategic growth asset.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue growth ~28%\u003c\/li\u003e\n\u003cli\u003eSemiconductor equipment market \u0026gt;$150B (2024 onshoring impact)\u003c\/li\u003e\n\u003cli\u003eEBITDA margins ~25% for niche testing\u003c\/li\u003e\n\u003cli\u003eHigh barriers: cleanrooms, capital, PhD staff\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins' Stars: €4.6bn growth engine—18–35% CAGRs, €860m R\u0026amp;D\/capex, 25–35% EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins’ high-growth Stars (Biopharma discovery, Advanced Genomics, BioTesting agroscience, Digital testing, EAG labs) drove ~€4.6bn revenue 2024–25 with 18–35% segment CAGRs, market shares 14–28%, R\u0026amp;D\/capex ~€860m (2023–25), and EBITDA expansion to ~25–35% in niche units.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024–25 revenue\u003c\/th\u003e\n\u003cth\u003eCAGR\u003c\/th\u003e\n\u003cth\u003eMarket share\u003c\/th\u003e\n\u003cth\u003eCapex\/R\u0026amp;D\u003c\/th\u003e\n\u003cth\u003eEBITDA\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharma discovery\u003c\/td\u003e\n\u003ctd\u003e€1.1bn\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003e14%\u003c\/td\u003e\n\u003ctd\u003e€220m\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvanced Genomics\u003c\/td\u003e\n\u003ctd\u003e€1.1bn\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e€240m\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioTesting (agro)\u003c\/td\u003e\n\u003ctd\u003e€2.1bn\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e€180m\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital testing\u003c\/td\u003e\n\u003ctd\u003e€120m\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEAG labs\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG-style review of Eurofins' units: Stars, Cash Cows, Questions, Dogs—investment, hold, divest guidance with competitive and trend context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing each Eurofins business unit in a quadrant for rapid portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoutine Food and Feed Safety Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoutine food and feed safety testing is Eurofins Scientifics foundational cash cow, holding an estimated global market share above 15% in a mature testing market growing ~3–4% annually (2024 data).\u003c\/p\u003e\n\u003cp\u003eHigh-volume, standardized assays produce strong operating cash flow—Eurofins reported €1.1bn adjusted operating cash flow in 2024—driven by economies of scale and lab network efficiency.\u003c\/p\u003e\n\u003cp\u003eCapital intensity is moderate; typical lab CAPEX under €50k per new routine line lets profits fund R\u0026amp;D and acquisitions in high-growth areas like genomics and environmental testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnvironmental Water and Soil Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins Scientific holds leading market share in environmental water and soil analysis, with the global environmental testing market at ~€15bn in 2024 and Eurofins’ segment revenues ~€1.1bn in 2024, reflecting high share in mature, regulation-driven demand.\u003c\/p\u003e\n\u003cp\u003eThese services deliver predictable, recurring revenue—service contracts with municipalities and industry average multi-year terms—requiring minimal marketing or capex, supporting stable EBITDA margins around 20% in 2024.\u003c\/p\u003e\n\u003cp\u003eCash from these steady contracts funds corporate debt reduction and dividends: Eurofins paid €0.80 per share in 2024 and reduced net debt by ~€150m in 2024, showing cash-cow utility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Pharmaceutical Quality Control Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoutine batch release and stability testing for established drugs at Eurofins Scientific generated roughly €420m in 2024 revenue within pharmaceuticals, representing a high-market-share, low-growth cash cow with global market growth under 3% annually.\u003c\/p\u003e\n\u003cp\u003eStandardized methods and validated facilities keep unit operating margins near 30% and require mainly maintenance CAPEX (~1–2% of sales), preserving strong free cash flow.\u003c\/p\u003e\n\u003cp\u003eAs a liquidity source, this unit funded ~€150m of corporate investments in 2024 while needing only steady staffing and instrument upkeep to sustain throughput.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Product Testing and Certification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConsumer product testing and certification—covering textiles, toys, and cosmetics—is a mature, low-growth business where Eurofins Scientific is a global leader, delivering steady margins; in 2024 the Testing segment contributed roughly €1.8bn of group revenue, driving consistent free cash flow.\u003c\/p\u003e\n\u003cp\u003eMarket expansion tracks global trade volumes (~3–4% annual growth pre-2024); stable demand means high cash generation with low capex, funding R\u0026amp;D-heavy divisions and cushioning volatility in specialty bioanalytical areas.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 Testing revenue ~€1.8bn\u003c\/li\u003e\n\u003cli\u003eMarket growth ≈3–4% pa tied to trade\u003c\/li\u003e\n\u003cli\u003eHigh FCF, low reinvestment needs\u003c\/li\u003e\n\u003cli\u003eProvides balance to R\u0026amp;D segments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eForensic Science and DNA Profiling Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEurofins Scientific’s forensic science and DNA profiling services are classic cash cows: long-term contracts with law enforcement and governments give high market share in a slow-growth segment (global forensic services ~3–4% CAGR to 2028), producing steady revenue—Eurofins reported EUR 1.2bn in specialized testing revenue in 2024—so focus is on operational efficiency and maximizing lab throughput.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable contracts with police\/agencies\u003c\/li\u003e\n\u003cli\u003eNon-discretionary demand, recession-proof\u003c\/li\u003e\n\u003cli\u003e2024: EUR 1.2bn specialized testing\u003c\/li\u003e\n\u003cli\u003eStrategy: cut unit costs, raise utilization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins’ high‑margin testing cash cows: €3.42bn revenue, strong FCF, €150m debt paydown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins’ cash cows—routine food\/feed testing, environmental analysis, pharma batch testing, consumer-product testing, and forensics—generated steady 2024 revenue: Testing €1.8bn, Specialized €1.2bn, Pharma batch €420m; segment margins ~20–30%, high FCF, low CAPEX, funding R\u0026amp;D and debt reduction (€150m net debt paydown, €0.80\/share dividend).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2024 Rev\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTesting\u003c\/td\u003e\n\u003ctd\u003e€1.8bn\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003ctd\u003e3–4% pa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialized\u003c\/td\u003e\n\u003ctd\u003e€1.2bn\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003ctd\u003e3–4% pa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma batch\u003c\/td\u003e\n\u003ctd\u003e€420m\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3% pa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eEurofins Scientific BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Eurofins Scientific BCG Matrix you'll receive after purchase—no watermarks, no demo content, just a fully formatted, analysis-ready report designed for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748590137721,"sku":"eurofins-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/eurofins-bcg-matrix.png?v=1772209654","url":"https:\/\/matrixbcg.com\/products\/eurofins-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}